Theravance Biopharma
TBPH
100 hedge funds and large institutions have $1.27B invested in Theravance Biopharma in 2016 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 43 increasing their positions, 23 reducing their positions, and 12 closing their positions.
87% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 23
65% more capital invested
Capital invested by funds: $770M → $1.27B (+$503M)
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
25% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 12
2% more funds holding
Funds holding: 98 → 100 (+2)
72% less call options, than puts
Call options by funds: $272K | Put options by funds: $972K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$20.9M |
| 2 |
WIM
Woodford Investment Management
London,
United Kingdom
|
+$18.8M |
| 3 |
Norges Bank
Oslo,
Norway
|
+$11M |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$7.65M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$6.23M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OppenheimerFunds
New York
|
-$14.8M |
| 2 |
SAM
Scion Asset Management
Saratoga,
California
|
-$7.37M |
| 3 |
RA
Royce & Associates
New York
|
-$4.09M |
| 4 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
-$3.06M |
| 5 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$2.78M |
TBPH Hedge Fund Activity: Q3 2016 in Review
100 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Theravance Biopharma (TBPH) for Q3 2016, worth a combined $1.27B — up 65% from $770M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new TBPH positions and 12 closed out — a net gain of 3 holders — while 43 added to existing stakes and 23 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $20.9M. The largest seller was OppenheimerFunds, exiting entirely with an estimated $14.8M sold.
- 100 institutional investors held Theravance Biopharma (TBPH) as of Q3 2016, up from 98 in Q2 2016.
- Funds reported $1.27B of Theravance Biopharma stock for Q3 2016, up 65% quarter-over-quarter.
- 15 funds opened new Theravance Biopharma positions in Q3 2016 and 12 closed out, a net change of +3 holders.
- The largest Theravance Biopharma buyer in Q3 2016 was Fidelity Investments, an estimated $20.9M added.
- The largest Theravance Biopharma seller in Q3 2016 was OppenheimerFunds, an estimated $14.8M sold.
Based on aggregated 13F filings for Q3 2016.